Massive Clinical Study Identifies Standard Amoxicillin as Preferred Treatment Over Broad-Spectrum Alternatives for Acute Sinusitis

Mass General Brigham study of 500,000 patients shows standard amoxicillin is as effective as broad-spectrum drugs for sinusitis, with fewer side effects.

By: AXL Media

Published: Apr 18, 2026, 11:10 AM EDT

Source: Information for this report was sourced from EurekAlert

Clinical Equivalence Found Between Standard and Broad-Spectrum Treatments

A retrospective investigation into the most common reason for adult antibiotic prescriptions in the United States has concluded that standard-dose amoxicillin is the optimal choice for treating uncomplicated acute sinusitis. Despite a lack of previous medical consensus, researchers found that the more powerful combination antibiotic, amoxicillin-clavulanate, did not yield superior recovery outcomes. Timothy Savage, an associate epidemiologist at Mass General Brigham, noted that identifying the most effective narrow-spectrum option is essential for patient safety, as these two drugs currently account for nearly 45% of all sinusitis-related prescriptions.

Large-Scale Insurance Data Analysis Spanning Six Years

The research team performed an exhaustive analysis of insurance claims data for 521,244 adults between the ages of 18 and 64 who were diagnosed with acute sinusitis from 2018 to 2023. By matching patients based on age, existing comorbidities, and their level of healthcare access, the investigators were able to isolate the specific effects of each antibiotic. The results indicated that treatment failure, defined as a patient needing to switch medications or return to an emergency department, was remarkably rare and statistically identical at approximately 3% for both treatment groups.

Secondary Infection Risks Linked to Broader Antibiotic Exposure

While the primary treatment outcomes were similar, the study identified a significant drawback to the use of amoxicillin-clavulanate. Patients who received the combination drug were at a slightly higher risk of contracting secondary bacterial or yeast infections compared to those on standard amoxicillin. This finding suggests that the broader-spectrum nature of clavulanate, which is designed to inhibit resistance enzymes, may unnecessarily disrupt a patient's natural microbial balance without providing a corresponding increase in the rate of primary infection clearance.